Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China stocks end lower after U.S. House clears delisting bill

12/03/2020 | 02:29am EDT

SHANGHAI, Dec 3 (Reuters) - China stocks ended lower on Thursday, weighed down by fresh tensions between Beijing and Washington after the U.S. House of Representatives passed a bill that threatens to delist Chinese companies from U.S. stock exchanges.

** Both Democrats and Donald Trump's fellow Republicans echoed the president's hard line against Beijing, which has became fiercer this year as Trump blamed China for the coronavirus ravaging the United States.

** Sino-U.S. relations have been a key factor influencing market sentiment since the outbreak of the trade war in 2018. On Wednesday, U.S. President-elect Joe Biden told the New York Times that he will not immediately cancel the trade agreement that President Donald Trump struck with China nor take steps to remove tariffs on Chinese exports.

** At the close, the Shanghai Composite index was down 0.21% at 3,442.14, while the blue-chip CSI300 index was down 0.2%.

** The smaller Shenzhen index ended up 0.08% and the start-up board ChiNext Composite index was higher by 1.101%.

** Vaccine-related stocks helped limit losses in the index, after the Institute of Microbiology at the Chinese Academy of Sciences said it worked with China's Chongqing Zhifei to carry out phase III trial of a coronavirus vaccine in China's Hunan province in November. The company was up 4.6% at market close, while the healthcare sub-index rose 2.7%.

** Vaccine stocks were also boosted after Britain approved Pfizer Inc's COVID-19 vaccine, raising hopes that the coronavirus pandemic, which has so far killed nearly 1.5 million people globally, could potentially be brought under control.

** Around the region, MSCI's Asia ex-Japan stock index was firmer by 0.27%, while Japan's Nikkei index closed up 0.03%. (Reporting by Winni Zhou and Andrew Galbraith; Editing by Vinay Dwivedi)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 1.50% 157.89 End-of-day quote.6.75%
NIKKEI 225 -1.80% 27283.59 Real-time Quote.-0.59%
S&P/CITIC 300 INDEX -0.02% 4335.68 Delayed Quote.-5.61%
S&P/CITIC 50 INDEX -0.04% 4027.69 Delayed Quote.-13.64%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
07/18CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : Zhifei Biological's COVID-19 Vaccine Reta..
MT
06/28Are Chinese COVID-19 shots effective against the Delta variant?
RE
06/11Chongqing Zhifei Biological Products Co., Ltd. Approves 2020 Profit Distribut..
CI
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/20Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Dividend for th..
CI
04/19Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
04/19CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China trials mixing of CanSinoBIO's and Z..
RE
03/15CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China IMCAS's COVID-19 vaccine obtained e..
RE
02/02Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect..
RE
More news
Financials
Sales 2021 26 005 M 4 025 M 4 025 M
Net income 2021 7 311 M 1 132 M 1 132 M
Net cash 2021 4 294 M 665 M 665 M
P/E ratio 2021 34,9x
Yield 2021 0,69%
Capitalization 253 B 39 096 M 39 100 M
EV / Sales 2021 9,55x
EV / Sales 2022 7,39x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 157,89 CNY
Average target price 224,93 CNY
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Xin Rong Zhang Independent Director
Bao Kui Liu Independent Director
Sector and Competitors